Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from a buy rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the company. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. Barclays upped their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. Needham & Company LLC raised their price objective on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. UBS Group lifted their price objective on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research report on Friday, September 11th. Finally, The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $337.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $293.45.

Jazz Pharmaceuticals Stock Up 3.3%

Shares of JAZZ stock opened at $234.76 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.58 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals has a 12 month low of $128.80 and a 12 month high of $266.38. The stock has a market cap of $15.07 billion, a P/E ratio of 79.85, a P/E/G ratio of 0.44 and a beta of 0.38. The company has a 50 day simple moving average of $229.39 and a two-hundred day simple moving average of $217.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the company posted $8.13 EPS. The company’s revenue was up 10.4% compared to the same quarter last year. On average, research analysts expect that Jazz Pharmaceuticals will post 11.08 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $215.84, for a total value of $1,295,040.00. Following the completion of the sale, the director owned 339,875 shares in the company, valued at approximately $73,358,620. This represents a 1.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,413 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total value of $326,911.68. Following the completion of the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at $1,506,616.32. The trade was a 17.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 102,534 shares of company stock worth $25,185,243. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in JAZZ. Aberdeen Group plc boosted its stake in shares of Jazz Pharmaceuticals by 16.5% in the third quarter. Aberdeen Group plc now owns 97,422 shares of the specialty pharmaceutical company’s stock worth $22,555,000 after acquiring an additional 13,816 shares during the period. JW Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $2,547,000. Russell Investments Group Ltd. lifted its holdings in Jazz Pharmaceuticals by 50.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock worth $17,696,000 after purchasing an additional 25,671 shares in the last quarter. Eurizon Capital SGR S.p.A. boosted its stake in Jazz Pharmaceuticals by 46.1% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $757,000 after purchasing an additional 1,029 shares during the period. Finally, Maryland State Retirement & Pension System boosted its stake in Jazz Pharmaceuticals by 19.0% in the 3rd quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock worth $841,000 after purchasing an additional 580 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets.

Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

Jazz expanded its portfolio through acquisitions, including the 2021 acquisition of GW Pharmaceuticals, which added Epidiolex and other cannabinoid-based medicines.